Moleculin Biotech shares slide 63.53% after $9.3 million offering priced at $0.75
AI Market Summary
Moleculin Biotech's steeply discounted $9.3m equity raise, coupled with warrant overhang, amplified dilution fears and triggered a sharp selloff. Concurrently, blinded MIRACLE trial readouts (37% composite remission) screened weaker than prior unblinded interim results, reinforcing uncertainty around efficacy while final unblinding remains months away. The catalyst is idiosyncratic, but it underscores small-cap biotech financing and data-risk sensitivity.
Impact level
● Low
Affected assets
NCSKMRNA2USD/USDT-4.01%
AI Insight · NCSKMRNA2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Moleculin Biotech (MBRX) said it priced a $9.3 million public offering at $0.75 per share, prompting investor concerns about heavy dilution. The company also reported new blinded MIRACLE trial data showing a 37% composite complete remission rate, below the up to 57% seen in an unblinded June 2026 interim readout. The stock fell 63.53% to $0.88, according to Benzinga Pro data.
